• 日期: 2024-06-11
  • 标签: 常规

Wilms Tumor Treatment Advances: A Comprehensive Review

Wilms tumor, also known as nephroblastoma, is the most common type of kidney cancer in children. Treatment options for Wilms tumor have evolved significantly over the years, leading to improved survival rates. This review provides a comprehensive overview of the current treatment landscape, examining surgical management, chemotherapy regimens, radiation therapy strategies, and risk-adapted approaches.

Surgical Management

The cornerstone of Wilms tumor treatment remains surgical resection. The primary goal is to remove the tumor completely while preserving as much healthy kidney tissue as possible. The surgical approach depends on the size and location of the tumor, as well as the extent of involvement. Nephron-sparing surgery is increasingly utilized when feasible, aiming to preserve renal function.

Chemotherapy

Chemotherapy plays a crucial role in Wilms tumor treatment, both before and after surgery. The specific regimen depends on the tumor stage, histology, and risk factors. Common chemotherapy agents include:

  • Vincristine: A microtubule inhibitor that interferes with cell division.
  • Dactinomycin: An antibiotic that damages DNA and inhibits cell growth.
  • Adriamycin (doxorubicin): A powerful anti-cancer drug that can cause significant side effects.
  • Etoposide: A topoisomerase inhibitor that inhibits DNA replication.

Radiation Therapy

Radiation therapy is often used in conjunction with surgery and chemotherapy, particularly in patients with higher-risk disease. It helps to eliminate residual tumor cells and reduce the risk of recurrence. Radiation therapy is delivered to the tumor bed and surrounding tissues.

Risk-Adapted Therapy

Modern Wilms tumor treatment emphasizes a risk-adapted approach, tailoring therapy based on the individual patient's risk factors. This approach helps to balance the benefits of treatment with the potential side effects.

Treatment Outcomes

Overall, treatment outcomes for Wilms tumor have significantly improved in recent decades. The 5-year survival rate for patients with localized disease is now close to 90%. However, patients with metastatic disease or high-risk features continue to face challenges.

Future Directions in Research

Ongoing research is focused on improving treatment outcomes for all patients with Wilms tumor. Areas of active investigation include:

  • Novel chemotherapy agents: Exploring new drugs that are more effective and have fewer side effects.
  • Targeted therapies: Developing treatments that specifically target the genetic mutations driving tumor growth.
  • Personalized medicine: Tailoring treatment based on an individual's genetic profile and tumor characteristics.

References

  1. Dome JS, Huff V. Wilms Tumor Overview. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviewsﾮ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1298/

  2. Davidoff AM. Wilms Tumor. Adv Pediatr. 2012;59(1):247-267. doi:10.1016/j.yapd.2012.03.007

  3. Pritchard-Jones K, Bergeron C, de Camargo B, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumor (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2021;397(10274):1640-1650. doi:10.1016/S0140-6736(21)00539-6

  4. Green DM, Breslow NE, Beckwith JB, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1994;12(11):2126-2131. doi:10.1200/JCO.1994.12.11.2126

  5. Ehrlich PF, Hamilton TE, Gow KW, et al. Surgical management of Wilms tumor: a report from the National Wilms Tumor Study Group. J Pediatr Surg. 2006;41(1):164-171. doi:10.1016/j.jpedsurg.2005.10.013

  6. Davidoff AM. Wilms tumor. Curr Opin Pediatr. 2009;21(3):357-364. doi:10.1097/MOP.0b013e32832a6fd5

  7. Ritchey ML, Kelalis PP, Haase GM, et al. Preoperative therapy for intracaval and atrial extension of Wilms tumors. J Pediatr Surg. 1994;29(1):100-104. doi:10.1016/0022-3468(94)90020-5

  8. Furtw￤ngler R, Nourkami-Tutdibi N, Leuschner I, et al. The role of surgical biopsy in the management of patients with presumed unilateral Wilms tumor: a report from the Society of Pediatric Oncology (SIOP) nephroblastoma trial and study 9. J Pediatr Surg. 2013;48(8):1590-1594. doi:10.1016/j.jpedsurg.2013.02.043

  9. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-7321. doi:10.1200/JCO.2005.06.031

  10. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24(15):2352-2358. doi:10.1200/JCO.2005.04.6441

  11. Kieran K, Williams MA, Dome JS, et al. The role of radiation therapy in the management of Wilms' tumor. J Pediatr Hematol Oncol. 2002;24(9):717-721. doi:10.1097/00043426-200211000-00001

  12. Paulino AC. Treatment of stage I and II favorable histology Wilms' tumor: radiation or chemotherapy? Pediatr Blood Cancer. 2005;44(3):221-226. doi:10.1002/pbc.20268

  13. Ehrlich PF, Anderson JR, Ritchey ML, et al. Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor. J Clin Oncol. 2013;31(9):1196-1201. doi:10.1200/JCO.2012.43.6466

  14. Tournade MF, Com-Nougu￩ C, de Kraker J, et al. Results of the Sixth International Society of Pediatric Oncology Wilms Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms tumor. J Clin Oncol. 1993;11(6):1014-1023. doi:10.1200/JCO.1993.11.6.1014

  15. Davidoff AM, Giel DW, Jones DP, et al. The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor. The St. Jude Children's Research Hospital experience: 1999-2006. Cancer. 2008;112(9):2060-2070. doi:10.1002/cncr.23381

  16. Ehrlich PF, Hamilton TE, Gow KW, et al. Surgical management of Wilms tumor: a report from the National Wilms Tumor Study Group. J Pediatr Surg. 2006;41(1):164-171. doi:10.1016/j.jpedsurg.2005.10.013

  17. Geller JI, Ehrlich PF, Cost NG, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children's Oncology Group study AREN03B2. Cancer. 2019;125(12):2045-2053. doi:10.1002/cncr.31963

  18. Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004;101(7):1575-1583. doi:10.1002/cncr.20575

  19. Geller JI, Ehrlich PF, Cost NG, et al. Characterization of adolescent and pediatric renal cell carcinoma: a report from the Children's Oncology Group study AREN03B2. Cancer. 2019;125(12):2045-2053. doi:10.1002/cncr.31963

  20. Ritchey ML, Kelalis PP, Haase GM, et al. Preoperative therapy for intracaval and atrial extension of Wilms tumors. J Pediatr Surg. 1994;29(1):100-104. doi:10.1016/0022-3468(94)90020-5

Wilms Tumor Treatment Advances: A Comprehensive Review

原文地址: https://www.cveoy.top/t/topic/kTTV 著作权归作者所有。请勿转载和采集!

免费AI点我,无需注册和登录